Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Medpace Holdings's Sloan Ratio for the quarter that ended in Jun. 2026 was -10.47%.
As of Jun. 2026, Medpace Holdings has a Sloan Ratio of -10.47%, indicating there is a warning stage of accrual build up.
Medpace Holdings (NAS:MEDP) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Medpace Holdings has a Sloan Ratio of -10.47%, indicating there is a warning stage of accrual build up.
Medpace Holdings Sloan Ratio % Related Terms
Medpace Holdings Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Medpace Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Sloan Ratio % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Medpace Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Medpace Holdings's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was 111.135 (Sep. 2025 ) + 135.133 (Dec. 2025 ) + 123.87 (Mar. 2026 ) + 121.362 (Jun. 2026 ) = $492 Mil.
Medpace Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 246.209 (Sep. 2025 ) + 192.652 (Dec. 2025 ) + 151.788 (Mar. 2026 ) + 162.011 (Jun. 2026 ) = $753 Mil.
Medpace Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -10.66 (Sep. 2025 ) + -4.473 (Dec. 2025 ) + -6.748 (Mar. 2026 ) + -23.885 (Jun. 2026 ) = $-46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEDP) has a Sloan Ratio % of -10.47% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Medpace Holdings and its competitors.
Is Medpace Holdings' Sloan Ratio % too high?
Medpace Holdings' current Sloan Ratio % is -10.47%. Overall, Medpace Holdings has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Sloan Ratio % compare to GH and ICLR?
Medpace Holdings' Sloan Ratio % of -10.47% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Diagnostics & Research company?
A good Sloan Ratio % depends on the Medical Diagnostics & Research industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Sloan Ratio % is -10.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (MEDP) is currently considered Fairly Valued. The stock's GF Value™ is $531.14, compared to a current price of $576.42 — trading 8.5% above its estimated fair value. The current Sloan Ratio % is -10.47%. Medpace Holdings' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Medpace Holdings (MEDP), the current Sloan Ratio % is -10.47% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of $576.42 is trading 8.5% above its estimated GF Value™ of $531.14.
GuruFocus considers Medpace Holdings to be Fairly Valued.
Key valuation signals for MEDP:
Sloan Ratio %: -10.47%
GF Value™: $531.14 vs. price of $576.42 (8.5% above fair value)
No single metric tells the full story. See the MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
97GF Score
Get the complete analysis for MEDP
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDP has been successfully added to your 
